

# Gilda Tachedjian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6096497/publications.pdf>

Version: 2024-02-01

101  
papers

4,552  
citations

94433

37  
h-index

114465

63  
g-index

107  
all docs

107  
docs citations

107  
times ranked

4877  
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of lactic acid production by probiotic <i>Lactobacillus</i> species in vaginal health. <i>Research in Microbiology</i> , 2017, 168, 782-792.	2.1	336
2	Contraction of the type I IFN locus and unusual constitutive expression of <i>IFN-<math>\lambda</math></i> in bats. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2696-2701.	7.1	272
3	Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. <i>Frontiers in Physiology</i> , 2015, 6, 164.	2.8	240
4	The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 219-228.	1.1	188
5	Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. <i>Mucosal Immunology</i> , 2017, 10, 1480-1490.	6.0	158
6	Decoding the Membrane Activity of the Cyclotide Kalata B1. <i>Journal of Biological Chemistry</i> , 2011, 286, 24231-24241.	3.4	155
7	N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance. <i>PLoS Medicine</i> , 2007, 4, e335.	8.4	151
8	Structure Activity Relationship of Dendrimer Microbicides with Dual Action Antiviral Activity. <i>PLoS ONE</i> , 2010, 5, e12309.	2.5	147
9	SPL7013 Gel (VivaGel <sup>®</sup> ) Retains Potent HIV-1 and HSV-2 Inhibitory Activity following Vaginal Administration in Humans. <i>PLoS ONE</i> , 2011, 6, e24095.	2.5	139
10	Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. <i>Virus Research</i> , 2008, 134, 147-156.	2.2	135
11	Vaginal concentrations of lactic acid potentially inactivate HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2015-2025.	3.0	135
12	Phosphatidylethanolamine Binding Is a Conserved Feature of Cyclotide-Membrane Interactions. <i>Journal of Biological Chemistry</i> , 2012, 287, 33629-33643.	3.4	115
13	An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3'-azido-3'-deoxythymidine. <i>Journal of Virology</i> , 1996, 70, 8010-8018.	3.4	108
14	Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 7188-7193.	7.1	107
15	Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol. <i>PLoS Pathogens</i> , 2006, 2, e119.	4.7	95
16	Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. <i>Antiviral Research</i> , 2011, 90, 195-199.	4.1	83
17	The implausible <i>in vivo</i> role of hydrogen peroxide as an antimicrobial factor produced by vaginal microbiota. <i>Microbiome</i> , 2018, 6, 29.	11.1	81
18	Distinct Immune Responses Elicited From Cervicovaginal Epithelial Cells by Lactic Acid and Short Chain Fatty Acids Associated With Optimal and Non-optimal Vaginal Microbiota. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019, 9, 446.	3.9	76

#	ARTICLE	IF	CITATIONS
19	Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. <i>Journal of Virology</i> , 1996, 70, 7171-7181.	3.4	70
20	Altered Sensitivity to Antiviral Drugs of Herpes Simplex Virus Isolates from a Patient with the Acquired Immunodeficiency Syndrome. <i>Journal of Infectious Diseases</i> , 1990, 162, 731-734.	4.0	69
21	Anti-HIV-1 Activity of Lactic Acid in Human Cervicovaginal Fluid. <i>MSphere</i> , 2018, 3, .	2.9	66
22	Role of Residues in the Tryptophan Repeat Motif for HIV-1 Reverse Transcriptase Dimerization. <i>Journal of Molecular Biology</i> , 2003, 326, 381-396.	4.2	64
23	Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B Virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds. <i>Journal of Medical Virology</i> , 1990, 31, 90-97.	5.0	61
24	Clinical Effects and In Vitro Studies of Trifluorothymidine Combined with Interferon- $\alpha$ for Treatment of Drug-Resistant and -Sensitive Herpes Simplex Virus Infections. <i>Journal of Infectious Diseases</i> , 1992, 166, 108-112.	4.0	60
25	Differential Evolution of Antiretroviral Restriction Factors in Pteropid Bats as Revealed by APOBEC3 Gene Complexity. <i>Molecular Biology and Evolution</i> , 2018, 35, 1626-1637.	8.9	59
26	Analysis of mutations and suppressors affecting interactions between the subunits of the HIV type 1 reverse transcriptase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 6334-6339.	7.1	56
27	The Packaging and Maturation of the HIV-1 Pol Proteins. <i>Current HIV Research</i> , 2005, 3, 73-85.	0.5	55
28	Mutations That Abrogate Human Immunodeficiency Virus Type 1 Reverse Transcriptase Dimerization Affect Maturation of the Reverse Transcriptase Heterodimer. <i>Journal of Virology</i> , 2005, 79, 10247-10257.	3.4	54
29	Discovery of Retroviral Homologs in Bats: Implications for the Origin of Mammalian Gammaretroviruses. <i>Journal of Virology</i> , 2012, 86, 4288-4293.	3.4	52
30	Identification of diverse groups of endogenous gammaretroviruses in mega- and microbats. <i>Journal of General Virology</i> , 2012, 93, 2037-2045.	2.9	48
31	Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. <i>FEBS Letters</i> , 2005, 579, 379-384.	2.8	46
32	The NRTIs Lamivudine, Stavudine and Zidovudine Have Reduced HIV-1 Inhibitory Activity in Astrocytes. <i>PLoS ONE</i> , 2013, 8, e62196.	2.5	46
33	Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. <i>FEBS Journal</i> , 2002, 269, 5103-5111.	0.2	45
34	Maturation of the HIV reverse transcription complex: putting the jigsaw together. <i>Reviews in Medical Virology</i> , 2009, 19, 324-337.	8.3	45
35	Identification of diverse full-length endogenous betaretroviruses in megabats and microbats. <i>Retrovirology</i> , 2013, 10, 35.	2.0	45
36	Characterisation of Foscarnet-Resistant Strains of Human Immunodeficiency Virus Type 1. <i>Virology</i> , 1995, 212, 58-68.	2.4	44

#	ARTICLE	IF	CITATIONS
37	Antiretroviral Compounds: Mechanisms Underlying Failure of HAART to Eradicate HIV-1. <i>Current Medicinal Chemistry</i> , 2005, 12, 1705-1719.	2.4	44
38	Evaluation of a Low Cost Reverse Transcriptase Assay for Plasma HIV-1 Viral Load Monitoring. <i>Current HIV Research</i> , 2005, 3, 183-190.	0.5	37
39	Dimerization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase as an Antiviral Target. <i>Current Pharmaceutical Design</i> , 2006, 12, 1879-1894.	1.9	35
40	Bats and Rodents Shape Mammalian Retroviral Phylogeny. <i>Scientific Reports</i> , 2015, 5, 16561.	3.3	31
41	Infectious KoRV-related retroviruses circulating in Australian bats. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 9529-9536.	7.1	31
42	Lactic acid-containing products for bacterial vaginosis and their impact on the vaginal microbiota: A systematic review. <i>PLoS ONE</i> , 2021, 16, e0246953.	2.5	29
43	Host and Viral Proteins Modulating Ebola and Marburg Virus Egress. <i>Viruses</i> , 2019, 11, 25.	3.3	28
44	Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51ÅkDa subunit of HIV-1 RT. <i>Biochemical Journal</i> , 2007, 404, 151-157.	3.7	22
45	N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. <i>Aids</i> , 2010, 24, 317-319.	2.2	22
46	Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6979-6984.	7.1	22
47	Combined oral contraceptive pill-exposure alone does not reduce the risk of bacterial vaginosis recurrence in a pilot randomised controlled trial. <i>Scientific Reports</i> , 2019, 9, 3555.	3.3	22
48	Cellular Topoisomerase I Activity Associated with HIV-1. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 1245-1250.	1.1	21
49	N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. <i>Aids</i> , 2010, 24, 659-667.	2.2	21
50	HERV-K Gag RNA and Protein Levels Are Elevated in Malignant Regions of the Prostate in Males with Prostate Cancer. <i>Viruses</i> , 2021, 13, 449.	3.3	21
51	Impact of Residues in the Nonnucleoside Reverse Transcriptase Inhibitor Binding Pocket on HIV-1 Reverse Transcriptase Heterodimer Stability. <i>Current HIV Research</i> , 2008, 6, 130-137.	0.5	20
52	Combination anti-HIV therapy via tandem release of prodrugs from macromolecular carriers. <i>Polymer Chemistry</i> , 2016, 7, 7477-7487.	3.9	20
53	Sensitive Assessment of the Virologic Outcomes of Stopping and Restarting Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. <i>PLoS ONE</i> , 2013, 8, e69266.	2.5	19
54	Why Do We Need New Drug Classes for HIV Treatment and Prevention?. <i>Current Topics in Medicinal Chemistry</i> , 2016, 16, 1343-1349.	2.1	19

#	ARTICLE	IF	CITATIONS
55	Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS. <i>Journal of Medical Virology</i> , 1995, 46, 238-243.	5.0	18
56	Analysis of the Contribution of Reverse Transcriptase and Integrase Proteins to Retroviral RNA Dimer Conformation. <i>Journal of Virology</i> , 2005, 79, 6338-6348.	3.4	17
57	The Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutation I132M Confers Hypersensitivity to Nucleoside Analogs. <i>Journal of Virology</i> , 2009, 83, 3826-3833.	3.4	17
58	Molecular dissection of an inhibitor targeting the HIV integrase dependent preintegration complex nuclear import. <i>Cellular Microbiology</i> , 2019, 21, e12953.	2.1	17
59	The effect of NNRTIs on HIV reverse transcriptase dimerization. <i>Current Opinion in Investigational Drugs</i> , 2003, 4, 966-73.	2.3	17
60	Relationship between enzyme activity and dimeric structure of recombinant HIV-1 reverse transcriptase. <i>Proteins: Structure, Function and Bioinformatics</i> , 2005, 60, 5-13.	2.6	16
61	Critical Review. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 1-7.	2.1	16
62	Investigation of Topoisomerase Inhibitors for Activity against Human Immunodeficiency Virus: Inhibition by Coumermycin A1. <i>Antiviral Chemistry and Chemotherapy</i> , 1990, 1, 131-138.	0.6	15
63	<b>Short Communication</b>: Impaired Fitness of Foscarnet-Resistant Strains of Human Immunodeficiency Virus Type 1. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 1059-1064.	1.1	14
64	Coresistance to Zidovudine and Foscarnet Is Associated with Multiple Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 3038-3043.	3.2	13
65	The Effect of Exogenous Sex Steroids on the Vaginal Microbiota: A Systematic Review. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 732423.	3.9	13
66	Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient. <i>Journal of Medical Virology</i> , 1994, 42, 207-211.	5.0	12
67	Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4 <sup>+</sup> T Cells following Latency Reversal. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	11
68	Retroviruses of Bats: a Threat Waiting in the Wings?. <i>MBio</i> , 2021, 12, e0194121.	4.1	11
69	High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo. <i>Virology</i> , 2016, 492, 1-10.	2.4	10
70	Targeting Human Immunodeficiency Virus Type 1 Assembly, Maturation and Budding. <i>Drug Target Insights</i> , 2007, 2, 117739280700200.	1.4	9
71	Enhancement of Human Immunodeficiency Virus Type 1 Replication Is Not Intrinsic to All Polyanion-Based Microbicides. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3565-3568.	3.2	9
72	No association between XMRV or related gammaretroviruses in Australian prostate cancer patients. <i>Virology Journal</i> , 2013, 10, 20.	3.4	9

#	ARTICLE	IF	CITATIONS
73	Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations. <i>Nucleic Acids Research</i> , 2015, 43, 3256-3271.	14.5	9
74	Risk of Subsequent HIV Infection Following Sexually Transmissible Infections Among Men Who Have Sex With Men. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz376.	0.9	9
75	A 30â€kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 137, 218-226.	4.3	9
76	Identification of residues involved in NS2 homodimerization and elucidation of their impact on the HCV life cycle. <i>Journal of Viral Hepatitis</i> , 2012, 19, 189-198.	2.0	8
77	Oxazole-Benzenesulfonamide Derivatives Inhibit HIV-1 Reverse Transcriptase Interaction with Cellular eEF1A and Reduce Viral Replication. <i>Journal of Virology</i> , 2019, 93, .	3.4	8
78	N348I in HIV-1 Reverse Transcriptase Counteracts the Synergy Between Zidovudine and Nevirapine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 153-157.	2.1	7
79	Lactic Acid, a Vaginal Microbiota Metabolite, Elicits an Anti-inflammatory Response from Vaginal and Cervical Epithelial Cells. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A238-A239.	1.1	7
80	Antiviral Activity of DG-35-VIII, a Potent Inhibitor of the Protease of Human Immunodeficiency Virus. <i>Antiviral Chemistry and Chemotherapy</i> , 1997, 8, 99-106.	0.6	6
81	Alteration of the Proline at Position 7 of the HIV-1 Spacer Peptide p1 Suppresses Viral Infectivity in a Strain Dependent Manner. <i>Current HIV Research</i> , 2007, 5, 69-78.	0.5	6
82	Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2015, 16, 1135-1153.	2.1	6
83	Synergistic Inhibition of Human Immunodeficiency Virus Type 1 in vitro by Interferon Alpha and Coumestrol A1. <i>Antiviral Chemistry and Chemotherapy</i> , 1992, 3, 183-188.	0.6	5
84	Effect of Reverse Transcriptase Inhibitors and Mutations on the Low-Cost Cavid Reverse Transcriptase Viral Load Assay. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 527-529.	2.1	5
85	Ubisol-Aqua <sup>TM</sup> : Coenzyme Q10 Prevents Antiretroviral Toxic Neuropathy in an In Vitro Model. <i>Current HIV Research</i> , 2010, 8, 232-239.	0.5	5
86	HIV-1 Infection of T Cells and Macrophages Are Differentially Modulated by Virion-Associated Hck: A Nef-Dependent Phenomenon. <i>Viruses</i> , 2013, 5, 2235-2252.	3.3	5
87	Vaginal Concentrations of Lactic Acid Potently Inactivate HIV-1 Compared to Short Chain Fatty Acids Present During Bacterial Vaginosis. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A228-A228.	1.1	5
88	Targeting human immunodeficiency virus type 1 assembly, maturation and budding. <i>Drug Target Insights</i> , 2007, 2, 159-82.	1.4	5
89	Virological significance, prevalence and genetic basis of hypersusceptibility to nonnucleoside reverse transcriptase inhibitors. <i>Sexual Health</i> , 2004, 1, 81.	0.9	4
90	Short Communication: Effect of Seminal Plasma on Functions of Monocytes and Granulocytes. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 553-556.	1.1	3

#	ARTICLE	IF	CITATIONS
91	A Summary of the Fifth Annual Virology Education HIV Microbiome Workshop. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 886-895.	1.1	2
92	Diethanolamine fusidate has no in vitro activity against the human immunodeficiency virus. <i>Medical Journal of Australia</i> , 1988, 149, 224-225.	1.7	2
93	The Impact of Over-The-Counter Lactic Acid Containing Vaginal Gels on the Integrity and Inflammatory State of the Vaginal Epithelium in vitro. <i>Frontiers in Reproductive Health</i> , 0, 4, .	1.9	2
94	Increasing prevalence of K65K and K66K in HIV-1 subtype B reverse transcriptase. <i>Aids</i> , 2016, 30, 2787-2793.	2.2	1
95	Role of RNase H Activity in NRTI/NNRTI Drug Resistance. , 2013, , 281-303.		1
96	In Vitro Effectiveness of a Combination of Zidovudine and Ansamycin Against Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 1988, 158, 895-895.	4.0	0
97	Drug Resistant SIV Strains Carrying Higher-Fidelity K65R and Q151N Reverse Transcriptase Mutations Are Less Fit In Vivo. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A185-A185.	1.1	0
98	Editorial (Thematic Issue: Current and Emerging Drug Targets for Human Immunodeficiency Virus). <i>Current Topics in Medicinal Chemistry</i> , 2015, 16, 1072-1073.	2.1	0
99	O05.4 The effect of the combined oral contraceptive pill on the vaginal microbiota of women treated for bacterial vaginosis. , 2019, , .		0
100	Editorial: Interplay of Infection and Microbiome. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 304.	3.9	0
101	A Summary of the Sixth International Workshop on Microbiome in HIV Pathogenesis, Prevention, and Treatment. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 173-180.	1.1	0